In modern society, adult rhinitis is often caused by environmental irritants, poor lifestyle habits, and allergies, with common symptoms including nasal itching, sneezing, runny nose, and congestion.
Budesonide nasal spray (Rhinocort) is widely recommended as a first-line treatment in numerous authoritative guidelines worldwide. This article explores the mechanism of action of budesonide, its synergistic use with oxymetazoline hydrochloride (Daphlin), and key considerations for combined therapy.
Mechanism of Budesonide (Rhinocort)
Budesonide is a nasal corticosteroid with potent anti-inflammatory effects. By binding to receptors in nasal mucosal cells, it suppresses the activation of inflammatory cells (such as eosinophils and T-lymphocytes) and reduces the release of inflammatory mediators (including histamine and leukotrienes). This mechanism effectively alleviates rhinitis symptoms.
Synergistic Effect: Budesonide (Rhinocort) and Oxymetazoline (Daphlin)
For patients with severe nasal congestion, swollen nasal mucosa can limit the distribution and delay the onset of budesonide’s effects. Combining budesonide with oxymetazoline (Daphlin) helps reduce nasal congestion and swelling, enhancing budesonide’s penetration and efficacy.
Oxymetazoline (Daphlin): A Rapid Decongestant
Oxymetazoline (Daphlin) is a decongestant that selectively activates α1-adrenergic receptors in nasal blood vessels, causing them to constrict quickly. This action reduces inflammation-induced mucosal swelling and congestion.
Studies, including “Observations on the Ciliary Toxicity of Common Decongestants,” highlight its rapid onset—72.2% of patients experience noticeable relief within one minute. Additionally, its effects last longer than other decongestants, with 70.4% of patients reporting relief for over five hours.
Benefits and Mechanism of Combined Therapy
The core strategy—”Reduce swelling first, then treat inflammation”—is endorsed by the 2022 Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis. Oxymetazoline quickly opens nasal passages, allowing budesonide to distribute more evenly and exert stronger anti-inflammatory effects.
Clinical studies, including “Evaluation of Daphlin Spray in Pediatric Chronic Rhinosinusitis,” confirm that combined therapy achieves faster symptom relief and longer-lasting effects compared to monotherapy.
Key Considerations for Combined Use
Application Sequence ：
First, administer oxymetazoline (Daphlin).
Wait 10–15 minutes for nasal passages to open.
Then, use budesonide (Rhinocort) for optimal efficacy.
Note: Oxymetazoline should not be used continuously for more than seven days. If symptoms persist, pause for 2–3 days before resuming under medical supervision.
Individual Variations
Patients may respond differently to treatment. Monitor symptoms closely and discontinue use if adverse effects (e.g., palpitations, dizziness, nasal dryness, or bleeding) occur. Consult a doctor if needed.
Conclusion
Adult rhinitis significantly impacts daily life and productivity. Combining budesonide nasal spray with oxymetazoline (Daphlin) using the “reduce swelling first, then treat inflammation” approach enhances therapeutic outcomes compared to single-drug regimens. However, always follow medical advice to ensure safety and efficacy.
Related topic：
